HU222249B1
(hu)
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
|
US5814600A
(en)
*
|
1991-05-24 |
1998-09-29 |
Amylin Pharmaceuticals Inc. |
Method and composition for treatment of insulin requiring mammals
|
AU7685894A
(en)
*
|
1993-09-07 |
1995-03-27 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
US6143718A
(en)
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
US6956026B2
(en)
|
1997-01-07 |
2005-10-18 |
Amylin Pharmaceuticals, Inc. |
Use of exendins for the reduction of food intake
|
US6410511B2
(en)
*
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US7312196B2
(en)
*
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US6136784A
(en)
*
|
1997-01-08 |
2000-10-24 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist pharmaceutical compositions containing insulin
|
US7101853B2
(en)
|
1997-05-06 |
2006-09-05 |
Amylin Pharmaceuticals, Inc. |
Method for treating or preventing gastritis using amylin or amylin agonists
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
US6936584B1
(en)
|
1998-02-13 |
2005-08-30 |
Amylin Pharmaceuticals, Inc. |
Mixed amylin activity compounds
|
US6933272B1
(en)
|
1998-09-22 |
2005-08-23 |
Erik Helmerhorst |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
US6506724B1
(en)
*
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6540982B1
(en)
*
|
2000-01-25 |
2003-04-01 |
Aeropharm Technology Incorporated |
Medical aerosol formulation
|
US6540983B1
(en)
*
|
2000-01-25 |
2003-04-01 |
Aeropharm Technology Incorporated |
Medical aerosol formulation
|
US6447750B1
(en)
*
|
2000-05-01 |
2002-09-10 |
Aeropharm Technology Incorporated |
Medicinal aerosol formulation
|
BR0116206A
(pt)
|
2000-12-14 |
2003-12-23 |
Amylin Pharmaceuticals Inc |
Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
|
AU2003235742B2
(en)
*
|
2002-01-08 |
2008-08-07 |
Amylin Pharmaceuticals, Llc |
Use of Amylin agonists to modulate triglycerides
|
US20040005997A1
(en)
*
|
2002-06-27 |
2004-01-08 |
The Procter & Gamble Company |
Methods for identifying compounds for regulating muscle mass of function using amylin receptors
|
AU2003278929A1
(en)
*
|
2002-10-18 |
2004-05-13 |
Amylin Pharmaceuticals, Inc. |
Treatment of pancreatitis with amylin
|
CA2525168A1
(en)
*
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide yy and pyy agonists
|
US8008255B2
(en)
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
US20070275877A1
(en)
*
|
2003-08-29 |
2007-11-29 |
Amylin Pharmaceuticals, Inc. |
Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
|
ATE471340T1
(de)
|
2004-02-11 |
2010-07-15 |
Amylin Pharmaceuticals Inc |
Peptide der amylin familie, verfahren zu deren herstellung und verwendung
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
JP5638177B2
(ja)
|
2004-02-11 |
2014-12-10 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
|
WO2005077072A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
WO2005079830A1
(en)
*
|
2004-02-23 |
2005-09-01 |
Paul Fraser |
Inhibitors of amyloid fibril formation and uses thereof
|
US7399744B2
(en)
*
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
JP2008515443A
(ja)
|
2004-10-08 |
2008-05-15 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
新規のアミリンファミリーポリペプチド−6(afp−6)アナログならびにそれらの製法および使用方法
|
DE102004051014A1
(de)
*
|
2004-10-20 |
2006-04-27 |
Rwth Aachen |
Chemisch modifizierte Peptidanaloga
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP2286838A3
(en)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Treatment of obesity and related disorders
|
KR101272402B1
(ko)
|
2004-12-13 |
2013-06-10 |
아스트라제네카 파마수티컬스 엘피 |
췌장 폴리펩티드 족 모티프, 폴리펩티드 및 이를 포함하는방법
|
EP2390264A1
(en)
*
|
2005-02-11 |
2011-11-30 |
Amylin Pharmaceuticals Inc. |
GIP analog and hybrid polypeptides with selectable propperties
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
WO2007022123A2
(en)
*
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
EP2457564A1
(en)
*
|
2005-03-11 |
2012-05-30 |
Endo Pharmaceuticals Solutions Inc. |
Controlled release formulations of octreotide
|
US7759312B2
(en)
*
|
2005-03-11 |
2010-07-20 |
Endo Pharmaceuticals Solutions Inc. |
Delivery of dry formulations of octreotide
|
ATE480255T1
(de)
|
2005-03-31 |
2010-09-15 |
Amylin Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
EP2241327A1
(en)
|
2006-03-15 |
2010-10-20 |
Novo Nordisk A/S |
Mixtures of Amylin and Insulin
|
KR20080110852A
(ko)
*
|
2006-03-23 |
2008-12-19 |
아밀린 파마슈티칼스, 인크. |
대사질환 치료용 엔도테린 및 엔도테린 수용체 작용제
|
MX2008012666A
(es)
*
|
2006-03-31 |
2008-10-13 |
Amylin Pharmaceuticals Inc |
Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.
|
US20090181890A1
(en)
*
|
2006-03-31 |
2009-07-16 |
Amylin Pharmaceuticals , Inc. |
Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
US7982018B2
(en)
*
|
2006-10-16 |
2011-07-19 |
Conjuchem, Llc |
Modified corticotropin releasing factor peptides and uses thereof
|
US8309522B2
(en)
|
2007-02-05 |
2012-11-13 |
Amylin Pharmaceuticals, Llc |
Neuromedin and FN-38 peptides for treating psychiatric diseases
|
KR20100036326A
(ko)
*
|
2007-06-29 |
2010-04-07 |
론자 아게 |
프람린타이드의 생산 방법
|
MX2010005345A
(es)
*
|
2007-11-14 |
2010-08-31 |
Amylin Pharmaceuticals Inc |
Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
|
WO2009158412A2
(en)
*
|
2008-06-25 |
2009-12-30 |
Endo Pharmaceuticals Solutions Inc. |
Sustained delivery of exenatide and other polypeptides
|
KR20110025974A
(ko)
|
2008-06-25 |
2011-03-14 |
엔도 파마슈티컬즈, 솔루션스 아이엔씨. |
이형제를 함유하는 옥트레오티드 이식물
|
US20110288235A1
(en)
*
|
2008-09-03 |
2011-11-24 |
Scinopharm Taiwan Ltd. |
Process for the Preparation of Pramlintide
|
AU2009288036A1
(en)
*
|
2008-09-03 |
2010-03-11 |
Scinopharm Taiwan, Ltd. |
Process for the preparation of pramlintide
|
EP2350118B1
(en)
|
2008-09-19 |
2016-03-30 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
CN116925238A
(zh)
|
2009-02-03 |
2023-10-24 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
JP2012523434A
(ja)
|
2009-04-10 |
2012-10-04 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
|
CA2764108A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
US9782454B2
(en)
|
2010-04-22 |
2017-10-10 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
CN103370083B
(zh)
|
2010-09-28 |
2016-11-16 |
艾米琳制药有限责任公司 |
具有增强的作用持续时间的工程化多肽
|
ES2641869T3
(es)
|
2010-09-28 |
2017-11-14 |
Aegerion Pharmaceuticals, Inc. |
Polipéptidos de fusión de leptina-ABD con duración de acción aumentada
|
JP2014521594A
(ja)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
長持続期間デュアルホルモンコンジュゲート
|
CN103957926B
(zh)
|
2011-07-08 |
2018-07-03 |
安米林药品有限责任公司 |
具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
|
EP2729481B1
(en)
|
2011-07-08 |
2018-10-17 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
US8846614B2
(en)
*
|
2011-08-25 |
2014-09-30 |
Usv Limited |
Process for the synthesis of 37-mer peptide pramlintide
|
EP2841089A4
(en)
|
2012-04-03 |
2016-03-16 |
Univ Boston |
COMPOSITIONS, PROCESSES AND ASSAYS WITH AMYLIN OR AMLYANANALOGA FOR ABETA PEPTIDE-MEDIATED ILLNESSES
|
US20150174209A1
(en)
|
2012-05-25 |
2015-06-25 |
Amylin Pharmaceuticals. Llc |
Insulin-pramlintide compositions and methods for making and using them
|
EP2968469A4
(en)
|
2013-03-15 |
2016-08-31 |
Longevity Biotech Inc |
PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
|
WO2015196174A1
(en)
|
2014-06-20 |
2015-12-23 |
Greene Howard E |
Infusion delivery devices and methods
|
AR109514A1
(es)
|
2016-09-09 |
2018-12-19 |
Zealand Pharma As |
Análogos de amilina
|
US10463717B2
(en)
|
2016-12-27 |
2019-11-05 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
|
WO2018144671A1
(en)
|
2017-02-01 |
2018-08-09 |
The Research Foundation For The State University Of New York |
Mutant islet amyloid polypeptides with improved solubility and methods for using the same
|
FR3082426A1
(fr)
|
2018-06-14 |
2019-12-20 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
|
CN110996905A
(zh)
|
2017-07-27 |
2020-04-10 |
阿道恰公司 |
至少包含人胰岛素a21g和餐时作用胰高血糖素抑制剂的可注射水溶液形式的组合物
|
PE20211202A1
(es)
|
2017-08-24 |
2021-07-05 |
Novo Nordisk As |
Composiciones de glp-1 y sus usos
|
FR3083085B1
(fr)
|
2018-06-29 |
2020-10-02 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
WO2019115411A1
(fr)
|
2017-12-07 |
2019-06-20 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
WO2019110797A1
(fr)
|
2017-12-07 |
2019-06-13 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
FR3083086A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
WO2019110788A1
(fr)
|
2017-12-07 |
2019-06-13 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
JP2021505616A
(ja)
|
2017-12-07 |
2021-02-18 |
アドシア |
アミリン、アミリンアゴニスト受容体またはアミリン類似体およびコポリアミノ酸を含む注射水溶液の形態の組成物
|
EP3764988A4
(en)
*
|
2018-03-15 |
2022-04-20 |
Adepthera LLC |
GEL-FORMING POLYPEPTIDES
|
FR3084586B1
(fr)
|
2018-08-03 |
2020-11-06 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
|
JP2022521266A
(ja)
*
|
2019-02-22 |
2022-04-06 |
ロヨラ メリーマウント ユニバーシティ |
アミロイドペプチドバリアント
|
AU2020382621A1
(en)
|
2019-11-13 |
2022-06-02 |
Amunix Pharmaceuticals, Inc. |
Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same
|
PE20221575A1
(es)
|
2020-02-18 |
2022-10-06 |
Novo Nordisk As |
Formulaciones farmaceuticas
|
CN117858892A
(zh)
|
2021-05-26 |
2024-04-09 |
恢复治疗瑞典公司 |
用于治疗和/或预防蛋白质病的组合物和方法
|